Table 1.
Patients Characteristics
| Characteristic | N (%)a |
|---|---|
| No. patients | 658 |
| Wuhan exposure | |
| Yes | 247 (37.5) |
| No | 411 (62.5) |
| Residence location | |
| Urban | 485 (73.8) |
| Rural | 173 (26.2) |
| Age, y | |
| ≤40 | 152 (23.1) |
| 40-54 | 364 (55.3) |
| 55-64 | 123 (18.7) |
| ≥65 | 19 (2.9) |
| Highest level of education | |
| Elementary school or less | 44 (6.7) |
| Middle school | 184 (28.0) |
| High school | 287 (43.6) |
| Bachelor’s degree or higher | 143 (21.7) |
| Annual income, US dollars | |
| <$7500 | 351 (53.3) |
| $7500-$15,000 | 203 (30.9) |
| $15,000-$43,000 | 95 (14.4) |
| >$43,000 | 9 (1.4) |
| Marital status | |
| Unmarried | 19 (2.9) |
| Married | 584 (88.9) |
| Divorced/widowed | 55 (8.2) |
| General health condition by self-identification | |
| Well | 269 (40.9) |
| Average | 227 (34.5) |
| Poor | 162 (24.6) |
| BC diagnosis time | |
| Within 1 year | 296 (45.0) |
| 1-5 years | 313 (47.6) |
| More than 5 years | 49 (7.4) |
| Stage of BC | |
| Early | 392 (59.6) |
| Metastatic | 115 (17.5) |
| Unknown | 151 (22.9) |
| Molecular subtype of BC | |
| TNBC | 127 (19.3) |
| Luminal | 177 (26.9) |
| HER2 | 196 (29.8) |
| Unknown | 158 (24.0) |
| History of BC surgery | |
| Yes | 628 (95.4) |
| No | 30 (4.6) |
| Recommend anti-cancer therapy | |
| Yes | 474 (72.0) |
| No | 184 (28.0) |
| Discontinued anticancer therapyb | |
| Endocrine therapy | 168 (32.9) |
| Targeted therapy | 105 (20.6) |
| Chemotherapy | 133 (26.1) |
| Radiotherapy | 27 (5.3) |
| Traditional Chinese medicine | 77 (15.1) |
| Duration of therapy interruptionc | |
| Less than 2 weeks | 135 (28.5) |
| 2-4 weeks | 102 (21.5) |
| Undefined | 131 (27.6) |
| Unknown | 88 (18.6) |
| No therapy discontinued | 18 (3.8) |
| CVC maintenance | |
| Not delayed | 112 (17.0) |
| Delayed | 164 (24.9) |
| No CVC | 382 (58.1) |
| Diagnosis of COVID-19 | |
| Yes | 1 (0.2) |
| No | 637 (96.8) |
| Unknown | 20 (3.0) |
| Close contact with patient with COVID-19 | |
| Yes | 48 (7.3) |
| No | 561 (85.3) |
| Unknown | 49 (7.4) |
| Worried aboutd | |
| Changed BC therapeutic regimen | 53 (5.5) |
| Delayed BC therapeutic regimen | 266 (27.5) |
| Suboptimal therapy for BC | 200 (20.7) |
| Infection of COVID-19 | 191 (19.8) |
| Discrimination | 21 (2.2) |
| Other | 101 (10.4) |
| None | 134 (13.9) |
Abbreviations: BC = breast cancer; COVID-19 = coronavirus disease 2019; CVC = central venous catheter; HER2 = human epidermal growth factor receptor 2; TNBC = triple negative breast cancer.
a
Percentages are weighted to account for the sample size (n = 658).
b
Percentages are weighted to account for the total responder size (n = 510).
c
Percentages are weighted to the size of the group of patients recommended for anti-cancer therapy (n = 474).
d
Percentages are weighted to account for the size of the total responder group (n = 966).